The National MS Society is partnering with organizations and supporting research that seeks to understand the impacts of COVID-19 for people living with MS, both in those who have the infection and those who do not. Other studies may address the impact of COVID-19 vaccines in people with MS.
Learn more about COVID-19 and MS
Remote interview study: Healthcare during the pandemic
Sponsor: University of Pittsburgh Medical Center
Time to complete: 45-50 minutes
Researchers at University of Pittsburgh Medical Center are seeking volunteers for a research study seeking to describe the barriers and facilitators to engagement in healthcare for people with disabilities during the COVID-19 pandemic. You may qualify if you are: a person with a disability or a care provider for someone with a disability; and at least 18 years old. Participation in the study involves one or two interviews (approximately 45-60 minutes). Interviews will be on the phone or on Zoom video conference. Participants will be compensated. For more information, contact study staff at 412-396-1511 or email
colbertam2@upmc.edu
Sponsor: iConquerMS
Time to Complete: 15-20 minutes
COVER-MS is a study that assesses the experiences of those diagnosed with MS who received the COVID-19 vaccines. If you have received the COVID-19 vaccine and are diagnosed with MS, visit the iConquerMS website to share your experience.
Learn More
Sponsor: iConquerMS™
Time to Complete: 15-20 minutes
iConquerMS is conducting this survey to learn more about how people affected by MS are dealing with the COVID-19 pandemic and what has been their personal experience with COVID-19.
Learn More
Submit Research Questions
Sponsor: iConquerMS™
Time to Complete: 1-2 minutes
iConquerMS is currently looking for research questions on the topic of COVID-19 and MS. What do you wish was better understood on this topic? Do you belong to a racial or ethnic minority group? They would especially like to hear from you. Communities of color have been affected more strongly by COVID-19 and often by MS as well.
Learn More